Rung 4 · Strong
Tarlatamab for small cell lung cancer that returns after chemotherapy
Longer survival than chemotherapy in a randomized trial.
TreatmentWith your doctor
What studies found
In DeLLphi-304 (509 patients), tarlatamab gave median survival of 13.6 months versus 8.3 months with standard chemotherapy. The FDA gave full approval on 19 November 2025.
The catch
It carries a boxed warning for life-threatening cytokine release syndrome and nerve toxicity.
What to do
If small cell lung cancer comes back after chemotherapy, ask whether tarlatamab is an option.
Sources
Rung 4 of 5, Strong: At least one large randomized trial, or very large consistent studies, on this exact question. How we score
To take it to your doctor, print this page.
Step by step
For the whole picture, from prevention and screening to treatment and life after, see the lung cancer page.
Related
- Tumor gene testing before lung cancer treatmentRung 5 · EstablishedWith your doctorRung 5 · EstablishedTreatmentWith your doctor
- Amivantamab plus lazertinib for advanced EGFR lung cancerRung 4 · StrongWith your doctorRung 4 · StrongTreatmentWith your doctor
- Durvalumab after chemoradiation for limited-stage small cell lung cancerRung 4 · StrongWith your doctorRung 4 · StrongTreatmentWith your doctor
- Immunotherapy around surgery for non-small cell lung cancerRung 4 · StrongWith your doctorRung 4 · StrongTreatmentWith your doctor
- Targeted pills after surgery or chemoradiation for EGFR or ALK lung cancerRung 4 · StrongWith your doctorRung 4 · StrongTreatmentWith your doctor